Organigram Appoints Vice President of Innovation
May 10 2021 - 6:00AM
Business Wire
Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX:
OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a
leading producer of cannabis, is pleased to announce the
appointment of Borna Zlamalik as the Company’s Vice President of
Innovation. Mr. Zlamalik will assume his new role effective
today.
In his new role, Mr. Zlamalik will draw upon his international
expertise in cannabis and cannabinoid-based product advancement,
commercialization, and pricing strategy to direct consumer product
innovation. As the Company’s Vice President, Innovation, Mr.
Zlamalik will oversee all R&D and product development. He will
also sit as one of Organigram’s representatives on the Steering
Committee for the recently announced Center of Excellence.
Mr. Zlamalik is an accomplished consumer packaged goods
marketer, most recently serving as Vice President, Marketing &
Communications, for The Valens Company. In that role, he focused on
recreational, health and wellness, therapeutic and medical product
development and brand marketing.
Mr. Zlamalik has also held senior roles as Scientific Regulatory
Affairs Director and Director of Global Strategy and Innovation at
JT International SA and Head of Marketing at JTI Macdonald Corp.
His distinguished career as a senior advertising executive has
included supporting the creative success of brands such as BMW
Group Canada, Bacardi, Coors Light and Fujifilm, among others.
“As we continue to expand our product portfolio and foster new,
industry-leading partnerships, Borna’s focus on growth and
innovation, along with his experience with speed to market
management, will be a tremendous addition to the Company’s
leadership team,” says Peter Amirault, executive chair,
Organigram.
Mr. Zlamalik will be based in Ontario but will oversee
Organigram’s product innovation efforts across the country. Mr.
Zlamalik holds a Bachelor’s degree from Western University.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and
TSX listed company whose wholly owned subsidiaries include:,
Organigram Inc., a licensed producer of cannabis and
cannabis-derived products in Canada and The Edibles and Infusions
Corporation, a cannabis infused soft chew and confectionary
manufacturer in Canada.
Organigram is focused on producing high-quality, indoor-grown
cannabis for patients and adult recreational consumers in Canada,
as well as developing international business partnerships to extend
the Company's global footprint. Organigram has also developed a
portfolio of legal adult use recreational cannabis brands including
The Edison Cannabis Company, Indi, Bag o’ Buds, SHRED and
Trailblazer. Organigram's primary facility is located in Moncton,
New Brunswick with a secondary edibles-focused manufacturing
facility in Winnipeg, Manitoba. The Company is regulated by the
Cannabis Act and the Cannabis Regulations (Canada).
This news release contains forward-looking information. Often,
but not always, forward-looking information can be identified by
the use of words such as “plans”, “expects”, “estimates”,
“intends”, “anticipates”, “believes” or variations of such words
and phrases or state that certain actions, events, or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information involves known and unknown
risks, uncertainties and other factors that may cause actual
results, events, performance or achievements of Organigram to
differ materially from current expectations or future results,
performance or achievements expressed or implied by the
forward-looking information contained in this news release. Risks,
uncertainties and other factors involved with forward-looking
information could cause actual events, results, performance,
prospects and opportunities to differ materially from those
expressed or implied by such forward-looking information include
factors and risks as disclosed in the Company’s most recent annual
information form, management’s discussion and analysis and other
Company documents filed from time to time on SEDAR (see
www.sedar.com) and filed or furnished to the Securities and
Exchange Commission on EDGAR (see www.sec.gov). Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Although the Company believes that the assumptions and factors used
in preparing the forward-looking information in this news release
are reasonable, undue reliance should not be placed on such
information and no assurance can be given that such events will
occur in the disclosed time frames or at all. The forward-looking
information included in this news release are made as of the date
of this news release and the Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210510005225/en/
For Investor Relations enquiries:
Amy Schwalm Vice President, Investor Relations
Amy.Schwalm@organigram.ca (416) 704-9057
For Media enquiries: Marlo Taylor
mtaylor@gagecommunications.ca
Organigram (NASDAQ:OGI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Organigram (NASDAQ:OGI)
Historical Stock Chart
From Sep 2023 to Sep 2024